0000899243-23-015960.txt : 20230620
0000899243-23-015960.hdr.sgml : 20230620
20230620161509
ACCESSION NUMBER: 0000899243-23-015960
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230615
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hrustanovic Gorjan
CENTRAL INDEX KEY: 0001821194
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 231025230
MAIL ADDRESS:
STREET 1: C/O KYMERA THERAPEUTICS, INC.
STREET 2: 200 ARSENAL YARDS, SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-15
0
0001815442
Kymera Therapeutics, Inc.
KYMR
0001821194
Hrustanovic Gorjan
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD. SUITE 230
WATERTOWN
MA
02472
1
0
0
0
0
Stock Option (Right to Buy)
27.67
2023-06-15
4
A
0
12000
0.00
A
2033-06-14
Common Stock
12000
12000
D
The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.
The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
/s/ Bruce Jacobs, as Attorney-in-Fact
2023-06-20